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Adult humanbonemarrow stromal cells (hBMSC) cultured for cell therapy require evaluation of potency and sta-
bility for safe use. Chromosomal aberrations upsetting genomic integrity in such cells have been contrastingly de-
scribed as “Limited” or “Signiﬁcant”. Previously reported stepwise acquisition of a spontaneous neoplastic
phenotype during three-year continuous culture of telomerized cells (hBMSC-TERT20) didn't alter a diploid kar-
yotype measured by spectral karyotype analysis (SKY). Such screening may not adequately monitor abnormal
and potentially tumorigenic hBMSC in clinical scenarios. We here used array comparative genomic hybridization
(aCGH) to more stringently compare non-tumorigenic parental hBMSC-TERT strains with their tumorigenic
subcloned populations. Conﬁrmation of a known chromosome 9p21 microdeletion at locus CDKN2A/B, showed
it also impinged upon the adjacentMTAP gene. Compared to reference diploid human ﬁbroblast genomic DNA,
the non-tumorigenic hBMSC-TERT4 cells had a copy number variation (CNV) in at least 14 independent loci.
The pre-tumorigenic hBMSC-TERT20 cell strain had further CNV including 1q44 gain enhancing SMYD3 expres-
sion and 11q13.1 loss downregulating MUS81 expression. Bioinformatic analysis of gene products reﬂecting
11p15.5 CNV gain in tumorigenic hBMSC-TERT20 cells highlighted networks implicated in tumorigenic progres-
sion involving cell cycle control and mis-match repair. We provide novel biomarkers for prospective risk assess-
ment of expanded stem cell cultures.
© 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Successful trials showing autologous stem cell subpopulations iso-
lated from human adult bone marrow tissue can be grown ex vivo and
subsequently reintroduced into patients to improve regenerative repair
of large bone defects (Quarto et al., 2001) have prompted need for stan-
dardized protocols to broaden the therapeutic scope (Panchalingam et
al., 2015). Associated with optimal cell sourcing approaches and cell
dosage requirements, themonitoring of procedural risk is of fundamen-
tal concern. Cultured cells are susceptible to stochastic acquisition of
hereditable changes thatmay subvert function or introduce a detrimental
outcome.Oncogenic changes can bemonitoredwith very sensitive specif-
ic techniques, yet thewide diversity of potential aberrations can confound
analysis and suitable biomarkers in the context of expanded “hBMSC”
populations have yet to be deﬁned. Signiﬁcant oncogenic changes can
range from discrete single codon mutations, gene ampliﬁcation, loss of
tumor suppressor gene function and epigenetic modiﬁcations. Since
such changes usually reﬂect or evoke chromosome abnormalities, it was
reasonable to propose that karyotypic analysis might sufﬁce to provide
an overview of whether the expanded stem cells are ﬁt for therapeutic
use (Saito et al., 2011), although this view has raised controversy
(Ferreira et al., 2012).
As a model system exemplifying accumulated genetic instability in
long-term continuously expanded cell cultures, we previously reported
that telomerized human bone marrow stromal cell strains hBMSC-
TERT (aka “hMSC-TERT”), ordinarily forming heterotopic bone when
transplanted with osteoconductive scaffold into immune deﬁcient mice
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(Simonsen et al., 2002), could eventually spontaneously evolve a neo-
plastic phenotype (Serakinci et al., 2004). Notably, however, the tumor-
igenic cells retained a normal diploid karyotype (Burns et al., 2008). To
improve detection of cytogenetic changes in cultured cells, we hereby
describe use of array comparative genomic hybridization (aCGH) to
identify segments of the genome existing as different copy number var-
iants (CNV). A reference human diploid ﬁbroblast genomic DNA was
compared to bone-forming hBMSC-TERT4 and hBMSC-TERT20 cell
strains, versus six sub-cloned tumorigenic cell lines derived from the ex-
tended culture neoplastic hBMSC-TERT20 strain of high population dou-
bling level (PDL) (Burns et al., 2005). Inclusion of single-cell derived
clones in our comparative analysis was advantageous, since aCGH may
fail to detect low-level mosaicism (≤10%) among a heterogeneous cell
strain (Elliott et al., 2010). Use of a progressive cell model with compre-
hensively measured growth kinetics in closely matched cell strains
allowed veriﬁcation of CNV reproducibility. The capacity to correlate ge-
netic aberrations with population doubling level and acquisition of a tu-
morigenic phenotype, helped identify speciﬁc CNV more likely to
harbour potentially causative genetic changes. Furthermore, prior
cytohistological data for cancer and differentiation pathway proteins in
hBMSC-TERT20 populations provided a veriﬁed context for exploring
the potential relevance of CNV-associated genes. A biological database
search tool for interacting genes/proteins conﬁrmed thatmanyCNV-spe-
ciﬁc genes were highly germane for tumorigenic progression, sharing
relevance with events prevalent in human cancers and sarcomas.
2. Materials and methods
2.1. Cell culture
From concern that broad casual use of the term MSC can introduce
confusion (Robey, 2017; Caplan, 2017) cells called “hMSC-TERT” in
our prior publications are here renamed hBMSC-TERT. The hBMSC
strain were cultured from a healthy male donor, 46, XY (age 33) trans-
duced at population doubling level (PDL) 12 with a retroviral vector
overexpressing the human telomerase reverse transcriptase gene
(hBMSC-TERT cells) was used to derive the hBMSC-TERT2, hBMSC-
TERT4 and hBMSC-TERT20 populations. Notably, the hTERT vector
wasn't taggedwith an independent co-selectablemarker, thus selection
relied purely on hTERT function driving growth beyond the senescence
observed in untransduced control primary hBMSC. As previously de-
scribed (Abdallah et al., 2005), eight passages after retroviral transduc-
tion (PDL 23), cells were partitioned into two passage regimes, with
split ratios of 1:2 or 1:4 to generate hBMSC-TERT2 or hBMSC-TERT4
populations. By PDL 47, hBMSC-TERT4 cells were further partitioned
into a 1:20 split ratio hBMSC-TERT20 population. Cell number was cal-
culated for each weekly passage. Prior analysis of neoplasia detected
loss of the p16INK4A/ARF locus in both hBMSC-TERT4 and hBMSC-
TERT20 cells, plus Kras Q61H mutation speciﬁc to hBMSC-TERT4 cells
and oncogene methylation of the DBCCR1/DBC1/BRINP1 promoter spe-
ciﬁc to hBMSC-TERT20 cells (Serakinci et al., 2004). At late passage
(PDL 440), hBMSC-TERT20 was used to derive single-cell sub-clones
designated -BB3, -BC8, -BD6, -BD11, CE8 and DB9 as described (Burns
et al., 2005). Subsequent histological analysis of hBMSC-TERT20 strains
and subclones examined a panel of cancer pathway prognostic bio-
markers (Burns et al., 2008). All cells were grown in phenol red-free
minimal essential medium (MEM) supplemented with 10% batch-test-
ed fetal bovine serum (FBS) and 1% penicillin/streptomycin (Gibco
Invitrogen) and maintained in a 5% CO2 humidiﬁed incubator at 37 °C.
2.2. Array-based Comparative Genomic Hybridization (aCGH)
GenomicDNAwasprepared using the PuregeneDNAPuriﬁcation Kit
(Qiagen). aCGHwas performed following the standard Agilent protocol
(V6.1). Brieﬂy, 700 ng of hBMSC-TERT lineage cell genomic DNA and
700 ng of reference diploid human ﬁbroblast genomic DNA 46,XX was
digested with AluI and RsaI and labeled with Cy5- or Cy3-dUTP
(Agilent). Following puriﬁcation with Microcon YM-30 ﬁlters
(Millipore), the labeled DNA yield and quality was checked on a
NanoDrop ND- 1000 UV-VIS Spectrophotometer (Thermo Fisher Scien-
tiﬁc, Waltham, MA, USA) and Agilent 2100 Bioanalyzer using
Bioanalyzer DNA High Sensitivity (Agilent Technologies). The labeled
samples were hybridized at 65 °C on Agilent dual colour arrays
(Sureprint G3, 2x400k cat.#G4825A; Agilent Technologies) for 24 h in
a rotator oven at 20 rpm. The annotation ﬁles corresponded to NCBI
build 36.1 of the human genome hg18 (March 2006) containing
411,056 60-mer probes. The comprehensive probe coverage allowed
genome-wide DNA CNV proﬁling focused on known genes, promoters,
miRNAs, pseudoautosomal and telomeric regions. Slides were washed
according to the protocol and scanned immediately at 2 μM resolution
on an Agilent G2565CA high-resolution scanner. Data was extracted
using Agilent Feature Extraction software and the resulting ﬁles were
processed with the Bioconductor limma package version 2.18.2, with
the raw data cleaned for background noise using the normexp convolu-
tion model. The resulting signal was processed using a quantiles-based
normalization procedure. Figures were generated with help of R soft-
ware ggplot2 implementation of the Grammar of Graphics.
2.3. RT-PCR Analysis of gene expression
Cellular RNA from hBMSC-TERT4 PDL-175 and hBMSC-TERT20 PDL-
337 was isolated using a single-step method with TRIzol (Invitrogen,
Taastrup, Denmark) according to manufacturer's instructions. First-
strand complementary cDNA was synthesized from 4 μg of total RNA
in accordance to a Revertaid H minus ﬁrst-strand cDNA synthesis kit
(Fermentas). Real-time polymerase chain reaction (RT-PCR) utilized
the StepOne PlusTM RT-PCR system (Applied Biosystems) with dou-
ble-strand DNA-speciﬁc SYBR→ Green I luminescent dye. In a total re-
action volume of 10 μL, 20 pmol/mL of each primer (DNA Technology
A/S or Euroﬁns, Ebersberg, Germany) and 10 pmol/mL for each refer-
ence gene was used with Fast SYBR® Green master mix (ABI). The
cycle conditions included an initial denaturation step at 95 °C for 20 s
and 40 cycles of 95 °C for 3 s, and 60 °C for 30 s. Normalization was
achieved via the reference gene β2-microglobulin (Lupberger et al.,
2002) (primer sequences in Supplementary Table 1).
In vivo xenograft of hBMSC-TERT cells in immuno-deﬁcient mice
hBMSC-TERT4 PDL 192 cells (5 × 105) combined with hydroxyl- apa-
tite/tricalcium phosphate 1–2 mm diameter granules (HA/β-TCP,
40 mg, Zimmer Scandinavia, Denmark) were transplanted subcutane-
ously into the dorsum of 8-week- old female NOD/SCID mice (NOD/
LtSz-Prkdcscid) as described (Burns et al., 2010). The transplants were
recovered eight weeks after transplantation, transferred to 4% neutral
buffered formalin for about 45 min, and then formic acid was added
for 2 days. Adopting standard histopathologic methods, the HA/β-TCP
implants were embedded in parafﬁn and 4-μm tissue sections were
stained with hematoxylin and eosin Y (H&E) (Bie & Berntsens
Reagenslaboratorium). Similarly, tumorigenic hBMSC-TERT20 PDL 480
cells (5 × 105) combinedwithMatrigel™were transplanted subcutane-
ously into the murine dorsal region and recovered two weeks after
transplantation, ﬁxed in 4% neutral buffered formalin as above and em-
bedded in parafﬁn for subsequent H&E staining of 4-μm tissue sections.
2.4. Bioinformatic characterization of copy number variable genes
To explore CNV relevance to known hBMSC-TERT cell biology, we
referenced prior molecular studies of tumorigenic events, including ge-
netic abnormalities and the expression of proteins involved in pathways
to cancer, the cell cycle, DNAmismatch repair and ossiﬁcation. Associa-
tions between such hBMSC-TERT qualiﬁed molecules and CNVs were
made using the Search Tool for Retrieval of Interacting Genes/Proteins
database (STRING, version 10.0), a database comprised known and pre-
dicted interactions, including direct (physical) and indirect (functional)
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associations based on genomic context, high throughput experiments,
conserved co-expression and previous knowledge (Szklarczyk et al.,
2015). In the ﬁrst instance, we mapped CNV associated with experi-
mentally known hBMSC-TERT pathways in cancer. Subsequently, to
conﬁrm the signiﬁcance of CNV speciﬁc to preneoplastic hBMSC-
TERT20 cells, software-derived high conﬁdence 1st shell network
interactors to SMYD3 (SET and MYND domain- containing protein 3)
and SIRT1 (Sirtuin 1) were used to map further CNV target associations
in epigenetic pathways. Software clustering tools included KEGG path-
way enrichment (Kanehisa et al., 2016).
2.5. Statistical analysis
For the real-time PCR analysis, a two-tailed t-test was applied to an-
alyze the expression of the CNV target genes in different hBMSC-TERT
cell populations. Fold-changes in gene expression between samples
with p values b 0.05 were considered signiﬁcant. The STRING v10 data-
base clustering coefﬁcient for interactions assumed a statistical back-
ground of the whole genome.
3. Results
3.1. Cell growth kinetics; passage split ratio associated tumorigenicity
As reported, the subculture passage split ratiowas an extrinsic factor
that inﬂuenced hBMSC-TERT cell growth rates and led to three passage
split ratio-speciﬁc growth curves (Fig. 1A). hBMSC-TERT20 cells, pas-
saged 1:20, showed the greatest step-wise acceleration in growth rate,
leading to a consistent DT of only 1.4 days by PDL-256, the point in
their evolution when xenografts were tumorigenic. Propagated with a
1:4 passage split ratio, hBMSC-TERT4 cells evolved doubling time
changes during passage from 4.6 days at PDL-74, to 4.2 days at PDL-95
and 1.5 days at PDL-169. The higher 1:4 seeding density for hBMSC-
TERT4 inﬂuenced culture contact inhibition (Abercrombie, 1970) since
cells were promptly in contact with each other after just one division.
In contrast, even 24 h after seeding, 1:20 split hBMSC-TERT20 cells
were distributed more autonomously on the culture surface. Previously
detected genetic and epigenetic aberrations discovered in the hBMSC-
TERT strains included a Kras Q61H oncogene activation detected in
hBMSC-TERT4 cells at PDL-169. At the time, we reported that hBMSC-
TERT4 cells at PDL-169 were nevertheless not tumorigenic. Conﬁrming
this was indeed the case, PDL 192 hBMSC-TERT4 cells subcutaneously
transplanted with osteoconductive scaffold, formed a trabecular bone
matrix tissue after 8 weeks in immune compromised mice, n = 4/4
(Fig. 1B). Thus, we were conﬁdent of comparing non-tumorigenic
(hBMSC-TERT4 and early hBMSC-TERT20 populations) versus tumori-
genic phenotypes (high PDL hBMSC-TERT20 subclones) when
interpreting the CNV observations.
3.2. Genetic aberrations conﬁrmed and discovered by array CGH
To generate array CGH proﬁles, glass slide anchored probes of
knownmapped sequences representing homogenous regions in the ge-
nome, competitively bound two samples of “reference” versus “test” ge-
nomic DNA, each labeled with differentiating ﬂuorescent dyes.
Consequently, copy number could be indirectly calculated from a ratio
Fig. 1. A, Long term growth curves of three independently grown, split ratio-speciﬁc, cell
populations derived from hBMSC-TERT cells in continuous culture for over 3 years. ( )
hBMSC-TERT2, passage split ratio 1:2; (■) hBMSC-TERT4, passage split ratio 1:4; ( )
hBMSC-TERT20, passage split ratio 1:20. Cell number was calculated weekly over the
indicated period. Time points indicate known genetic aberrations (Ink4a/ARF deletion,
Kras Q61H mutation and DBCCR1 methylation silencing), xenograft outcomes (bone or
tumor), array comparative genomic hybridization (aCGH) sampling, single cell
subclones derivation by limiting dilution and hBMSC-TERT20 spectral karyotyping
(SKY). B, Heterotopic bone formation by K-ras Q61H mutant hBMSC-TERT4 cells.
Histological analysis of 4 μm sections of decalciﬁed parafﬁn embedded implants
harvested 8 weeks after subcutaneous transplantation of hBMSC-TERT4 PDL-192 cells
with hydroxyapatite-tricalcium phosphate (HA-TCP) granules in immunodeﬁcient mice.
Hematoxylin and eosin pink stained new trabecular bone matrix, (B) within the HA-TCP
scaffold, contained numerous osteocytes within lacunae (solid arrows) and blood
vessels (v) with adipocytes (open arrows) adjacent to haematopoietic cells (h). C,
Sarcoma formation by hBMSC-TERT20 cells. Histological analysis of 4 μm sections of
xenografts harvested two weeks after subcutaneous transplantation of hBMSC-TERT20
PDL-480 cells with Matrigel™. Scale bar = 100 μm.
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of ﬂuorochrome intensities proportional to the relative probe-spanning
chromosome abundance of the samples. Proﬁles for each chromosome
comprised a ranking of log2 ﬂuorescent ratios plotted according to the
probe's corresponding physical position on the genome. The plotted
data were normalized with a median set to log2(ratio) = 0 for regions
of no change; positive means represented duplicated whilst negative
means represented deleted regions in the test genome. Since results
were based on ﬂuorescent measurement, the signal was plotted as con-
tinuous even if the underlying biological process was discrete (relative
copy numbers of DNA sequences). N.B. The relative copy number
value in the test sample could vary due to heterogeneous incidence in
the cell population. For conﬁdence, aberrations with a minimum of
four probes in the region were chosen. One exception, at 11q13.1 had
an individual probe with a particularly strong signal reproduced in
most test samples. With very characteristic proﬁle patterns, the
hBMSC-TERT strains and isogenic expanded subclones conﬁrmed the
very high reproducibility of the aCGH approach.Microdeletions in chro-
mosome regions 1q21.1, 2q11.2, 2q21.1, 3q26.1, 9p21.3, 11p15.1,
15q24.2, 17q23.2, 21q11.2 and 22q11.23 were ubiquitous in both
hBMSC-TERT substrains and all subclones. The known p16INKa/ARF
microdeletion at 9p21.3, one of the clearest aberrations found (Fig.
2A), was now better deﬁned by 30 consecutive probes spanning the
CDKN2A, CDKN2B and adjacentMTAP loci (Fig. 2B). The CNV proﬁle in-
dicated the span of chromosome loss was the same for hBMSC-TERT4,
hBMSC-TERT20 and all the hBMSC-TERT20 subclones. The 9p21.3 CNV
seen in hBMSC-TERT4 had a probe deletion ratio range (−1 to −3)
that was substituted by a narrower range of larger ratios (−2 to−3)
in hBMSC-TERT20 cells and subclones, likely indicative of accruedmiss-
ing genomic segments. For the non-ubiquitous CNV, restricted to more
speciﬁc cell populations, there was a tendency for the CNV ratio be-
tween sample and control to be 1.
To more closely correlate CNV to the tumorigenic phenotype, we fo-
cused on CNV speciﬁc to the hBMSC-TERT20 strain and its tumorigenic
subclones (Table 1). Notably, two CNV absent in non-tumorigenic
hBMSC-TERT4 PDL 88 cells were found in the pre-tumorigenic
hBMSC-TERT20 PDL116 population and subsequent hBMSC-TERT20
PDL440 derived tumorigenic subclones; namely, a 1q44 gain (Fig. 3A)
and a microdeletion at 11q13.1 (Fig. 3B). The region concerning CNV
1q44 co-involved two probes targeting SMYD3 that encodes a histone
methyltransferase involved in the proliferation of cancer cells
(Hamamoto et al., 2004). The region lost by CNV 11q13.1 co-involved
MUS81, a crossover junction endonuclease. RT-PCR analysis of gene ex-
pression in hBMSC-TERT4 PDL 175 versus hBMSC-TERT20 PDL 337 con-
ﬁrmed that changes in relative expression agreed with expectations
from the corresponding CNV type. This was not the case for amore cen-
tromeric chromosome 11 control geneMAP3K11 outside the CNV region
(Fig. 3C). The chromosome showing most imbalances and CNV was
chromosome 11. Speciﬁc to all tumorigenic hBMSC-TERT20 subclones
we observed ampliﬁcation of the short (p) arm of chromosome 11 at
the telomeric region 11p15.5 (chr11:0–570,000) (Fig. 4A) comprising
37 genes from IFITM5 to PHRF1 including HRAS (Fig. 4B). This region
didn't involve a centromerically distal neighboring cluster of imprinted
Fig. 2.Array CGH proﬁle of chromosome subregion in hBMSC-TERT strains and subclones. A, The 9p21.3 deletion includedmultiple probes spanning a locus for CDKN2A, CDKN2B and exon
8 ofMTAP. Abscissa: Location of the probe on the genome. Ordinate: The log-ratio of the aCGH probe signal for sample versus reference genomic DNA. Positive and negative log-ratios
indicated ampliﬁcation or deletion respectively, ±1 indicates a gain or loss of one of the two alleles, larger -log ratios indicate missing genomic segments. Plotted dot size is
proportional to overall intensity of the probe signal. B, Chromosome 9 ideogram, red bar highlights the 9p21.3–250 kbp CNV region with UCSC database annotation for genes spanned
by chr9:21,850,000–22,100,000. Opposing red arrowheads represent the centrosomic region.
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genes associated with Beckwith-Wiedemann syndrome (BWS) and a
high risk of development of childhood sarcomas. Nonetheless, the
BWS region may remain relevant for sub-clone–CE8, since the CNV
log2 ratio for this particular clone was consistently 0.5 higher than the
other sub-clones, indicative of a full chromosome 11 imbalance. Our
analysis restricting the 11p15.5 ampliﬁed region window to chr11:0–
1000,000 to comprise at least a further 32 inﬂuenced genes (Fig. 4C),
was most likely a conservative estimate for hBMSC-TERT20-CE8.
3.3. Interacting Genes/Proteins suggest a CNV role in tumorigenesis
Tumorigenic events characterized from previous studies exploring
events in hBMSC-TERT20 cell tumorigenic progression (Serakinci et
al., 2004) (Burns et al., 2005) (Burns et al., 2008), provided a contextual
framework for exploring CNV relevance. The principle aspects of the
contextual framework could be described as follows: Driving hBMSC-
TERT characteristics, hTERT associated with many genes and proteins
belonging to KEGG pathways in cancer, including cell cycle regulators;
both CDKN2A gene locus products p16INK4a and alternate reading
frame p14arf, the CDKN2B gene product p15INK4B, the CDKN1A gene
product p21Cip1, the CDKN1B product p27Kip1, CCND1 derived Cyclin
D1 and tumor suppressor gene products RB1 and TP53 as well as cell
surface receptors EGFR and VEGFA. The latter two trophic factor recep-
tors also interacted with TP53 that in turn interacted with a series of
mismatch repair proteins MLH1, MSH2, PMS2 and MSH6 to establish a
cardinal role for TP53 in regulating cell cycle activity and conserving ge-
nomic stability. The cell cyclemachinery interactswith cytoskeleton dy-
namics, reﬂecting important external cues such as cell-cell or cell-
matrix adhesions thatmodulate activity of the cell autonomousprolifer-
ationmachinery through speciﬁc checkpoints. In turn, changes in extra-
cellular matrix organisation involving CD44, COL4A1, SPARC, COL1A1,
IBSP and BGN are key aspects of ossiﬁcation.
In addition to the CNV already mentioned above; 1q44, 9p21.3,
11p15.5 and 11q13.1, a further six CNV at 1q21.1, 2q11.2, 2q21.1,
11q13.1 (-BD6 speciﬁc), 17q23.21 and 22q11.23 (Fig. 5A–F), spanned
genes that could interact directly with the hBMSC-TERT contextual
framework in a manner shown schematically in Fig. 6A. This string da-
tabase interaction map for the hBMSC-TERT contextual framework
had an overall clustering coefﬁcient of 0.794 and more interactions
than would be predicted from chance, indicating the CNV were likely
to be biologically connected to tumorigenic events found in hBMSC-
TERT20 cells. As many as twenty CNV-speciﬁc interactors recruited in
this network were from the 23 STRING identiﬁed proteins within the
11p15.5 CNV chromosome gain locus, including a cluster of genes
encoding interferon-induced transmembrane protein family members.
In contrast, for the ubiquitous 1q21.1 CNV loss that also harbored 37
Refseq coding sequences, including non-annotated genes, only six
were identiﬁed by the STRING database of which just two, PPIAL4C
and NBPF10, interacted with the network. A KEGG pathway analysis of
the network indicated that ten of the a priori deﬁned contextual net-
work proteins (CCND1, CDKN1A, CDKN1B, COL1A1, COL4A1, EGFR,
IBSP, LAMA1, TP53, VEGFA) were components of the PI3K/AKT/mTOR
signaling network important for regulating the cell cycle. Notably, four
hypothetical gene products from the 11p15.5 CNV speciﬁc to the tumor-
igenic hBMSC-TERT20 sub-clones (AP2A2, PSMD13, SIRT3 and HRAS),
interacted with this pathway. Moreover, it was possible to derive addi-
tional networksmore speciﬁcally related to SMYD3 (Fig. 6B) and epige-
netic signaling (Fig. 6C) (a total of 38 highly predicted functional
network partners from a total of 67 STRING identiﬁed gene products).
3.4. Evidence for CNV contributions to epigenetic deregulation
The STRING database for the contextual framework above didn't in-
dicate a direct interaction for the 1q44 CNV gain candidate gene SET and
MYND domain-containing protein 3 (SMYD3). Yet its relevance can be
predicted, as acetylation of the histone H3 TERT promoter region is
one of several targets for this histone methyltransferase (Liu et al.,
2007), a principal epigenetic modiﬁcation of chromatin that can deter-
mine gene expression, genomic stability and cell mitosis. Thus, STRING
was used to identify 10 highly predicted SMYD3 partners, forming a
contextual framework for exploring SMYD3-related CNV relevance.
Eight SMYD3 predicted functional network partners directly interacted
with 13 predicted proteins from 58 STRING identiﬁed target genes
spanned by 6 CNV. Notably, the network involved the 9p21.3 CNV
genes andmost of the highly predicted SMYD3 functional network part-
ners interacted with HRAS from the 11p15.5 CNV (Fig. 6B).
Table 1
CNV in bone-forming hBMSC-TERT4 and hBMSC-TERT20 strains, versus hBMSC-TERT20 tumorigenic subclones.
Cytoband locus Copy number variation CNV size hBMSC-TERT4 hBMSC-TERT20 hBMSC-TERT20
(CNV) (kbp) PDL 88 PDL 116 BB3 BC8 BD6 BD11 CE8 DB9
1q21.1 Loss 1000 + + + + + + + +
1q44 Gain 300 + + + + + + +
2q11.2 Loss 100 + + + + + + + +
2q21.1 Loss 225 + + + + + + + +
3q26.1 Loss 120 + + + + + + + +
6q23.3 Loss 110 +
9p21.3 Loss 250 + + + + + + + +
11p15.5-q25 Gain 135,000 +
11p15.5 Gain 570 + + + + + +
11p15.4 Loss 400 +
11p15.1 Loss 40 + + + + + + + +
11q13.1 (a)a Loss 15 + + + + + + +
11q13.1 (b)a Loss 65 +
15q24.2 Loss 5 + + + + + + + +
17q23.2 Loss 50 + + + + + + + +
21q11.2 Loss 600 +
22q1123 Loss 30 + + + + + + + +
Xq21.33 Loss 60 +
a (a) chr11:65,375,000–65,390,000 (b) chr11:65,550,000–65,620,000.
Fig. 3. CNV speciﬁc for pre-tumorigenic hBMSC-TERT20 cells and tumorigenic subclones. A, Array CGHproﬁle for 1q44 in each cell type. Axes as described in Fig. 2. Plotted dot size proportional
to overall intensity of the probe signal. Chromosome1 ideogram, red bar highlights the 1q44 ~ 300kbpCNV region spanningUSCCdatabase annotated genes SMYD3, TFB2Mand chromosome1
open reading frame 71, C1orf71/consortinwithin chr1: 244,500,000–244,800,000. B, Array CGHproﬁle for 11q13.1 in each cell type. Chromosome 11 ideogram, red bar highlights the 11p13.1–
15 kbp CNV region spanning USCC database annotated genes SNX32, CFL1 and MUS81 within chr11:65,555,000–65,620,000. C, RT-PCR analysis for expression of 1q44 CNV SMYD3 gene,
11q13.1 MUS81 and a neighboring 11q13.1 gene outside the CNV region, MAP3K11. (*p b 0.05). Opposing red arrowheads represent the centrosomic region.
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The histone NAD dependent protein deacetylase Sirtuin (SIRT1) is
another epigenetic regulator of telomeric maintenance and highly rele-
vant to cell cycle, DNA repair and apoptosis, linking transcriptional reg-
ulation directly to intracellular energetics. Using STRING to identify
highly predicted SIRT1 partners resulted in a contextual framework in-
corporating 19 predicted proteins from 59 STRING identiﬁed genes
spanned by nine different CNV loci, again including the 9p21.3 CNV tar-
gets CDNK2A and CDKN2B that ordinarily inhibit histone acetylation
Fig. 4.CNVspeciﬁc for hBMSC-TERT20 tumorigenic subclones. A, ArrayCGHproﬁle for 11p15.5 in each cell type. Axes asdescribed in Fig. 2. Plotteddot size proportional to overall intensity of the
probe signal. B, Chromosome 11 ideogram, red bar highlights the 11p15.5 ~ 570 kbp CNV spanning USCC and Refseq database annotated genes including HRAS within chr11:0–570,000. C,
Chromosome 11 ideogram, red bar highlights the 11p15.5 ~ 450 kbp CNV speciﬁc to clone –CE8 cells spanning USCC and Refseq database annotated genes including PIDD, POLR2L and
CD151 within chr11:570,000–1000,000. This was a conservative estimate, CE8 CNV indicated whole chromosome 11 imbalance. Opposing red arrowheads represent the centrosomic region.
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(Fig. 6C). Thus, a high proportion of the STRING database identiﬁed CNV
candidate genes interacted with molecules known to have a key role in
epigeneticmodulation (57% in the hBMSC-TERT contextual network de-
rived from prior experimental data, 22% in a SMYD3 network, and 32%
in a SIRT1 network) representing effector proteins with critical roles
in cell signaling networks.
4. Discussion
A typical workﬂow for stem cell-based therapy includes stem cell
isolation, expansion, manipulation, preclinical evaluation, engraftment
and follow-up. Even promising alternative “non-whole cell” therapeutic
strategies e.g. decellularizedmatrix (Yamet al., 2016), extracellular ves-
icles (György et al., 2015) or targeted epigenetic conversion of endoge-
nous cells (Black et al., 2016), are unlikely to totally replace whole cells
as advanced therapymedical products (ATMP). Genetic drift of cultured
cells for any therapeutic productwill remain ofmajor concern regarding
consistency, functional efﬁcacy and safety (Furlani et al., 2009). Tradi-
tional in vivo tumorigenicity assays can be incompatible with recom-
mendations for minimal cell expansion time frames and prompt
patient application to minimise risk of genomic mutations (Wang et
al., 2013) (Froelich et al., 2013). Increased need for testing will accom-
pany non-hBMSC cells procured as ATMP from other tissue sources
(Sacchetti et al., 2016) and innovative approaches to enhance cell ex-
pansion or function, e.g. hypoxic culture conditions can inﬂuence chro-
mosome stability (Ueyama et al., 2012) (Bigot et al., 2015) (Anderson et
al., 2016). Bioprocessing strategies for large-scale production of hBMSC
(Panchalingam et al., 2015) will need to meet regulatory authority
product characterization requirements (Mendicino et al., 2014). Suit-
able biomarker panels for improved prompt assessment of tumorigenic
risk pre- and post-engraftment (Goldring et al., 2011)would be of enor-
mous beneﬁt.
Potential problems in obtaining sufﬁcient mitotic spreads from rela-
tively slow-growing primary hBMSC have been largely overcome
(Hwang et al., 2013). In most cases, chromosomal G-banding or SKY
analysis generally suggested that the karyotype is relatively stable
(Chen et al., 2014) and cultured stromal cells from diverse tissue
sources aren't prone to neoplastic transformation (Roseti et al., 2014)
(Ruan et al., 2014). Nonetheless, a turbulent initial cell culture acclima-
tization phase may introduce transient genetic errors and karyotypic
abnormalities that diminish upon further passage because they fail to
confer an evolutionary growth advantage, i.e. detrimental non-sustain-
able phenotypes inducing cell senescence, growth arrest or apoptosis
(Stultz et al., 2016). In such contexts, monitoring the genetic stability
of clinical grade hBMSC during primary expansion by SKY karyotyping
may more readily help decide upon suitability for use, even if hBMSC-
TERT20 tumorigenicity arose in SKY “normal” diploid cells.
Array CGH is a sensitive approach for detecting cytogenetic abnor-
malities, in particular, the Agilent 400 K human array provided ge-
nome-wide CNV proﬁling without need for ampliﬁcation or
complexity reduction with comprehensive probe coverage enhanced
by emphasis on known genes, promoters, miRNAs, pseudoautosomal
and telomeric regions. However, since population variation may
lead to CNV in roughly 12% of the human genomic DNA of “healthy”
cells, setting safety thresholds is not necessarily straightforward.
Since aCGH is a method that relies on unique sequence probe
hybridisation it has limitations for the detection of repeat sequences,
pseudogenes and insight into the orientation or location of inser-
tions, e.g. failing to detect reciprocal translocations. Nonetheless,
sensitive detection for intragenic deletions can be obtained among
the various arrays available (Askree et al., 2013; Haraksingh et al.,
2017).
Deﬁning covert events indicative of tumorigenic predisposition is
particularly challenging, given the complexity of cell processes and dif-
ﬁculty in determining the timing of events and their consequences. De-
spite improved detection from array CGH, interpretation of the
signiﬁcance of the CNV event may be problematical and clinical rele-
vance requires careful interpretation (Hollenbeck et al., 2016) (Savola
et al., 2007) (Zhao and Zhao, 2016). To this end the hBMSC-TERT20
model presented several strong points. Independently acquired prior
data provided a contextual framework with which to assess CNV. The
long-term evolution of the tumorigenic phenotype and contrasting
non-tumorigenic closely-matched strains enabled comparisons to iden-
tify elusive “pre-neoplastic” events. Veriﬁcation of CNV persistence in
single-cell derived clones provided a test of clonal penetrance and
underscored likelihood that the CNV contributed to a persistent prolif-
erative growth advantage.
Our three-year hBMSC-TERT cell expansion model monitored cyto-
genetic abnormalities and stochastic events leading to tumorigenesis
in an isogenic context, providing insights for monitoring ATMP cell cul-
tures for tumorigenic risk. Initial suspicion that loss of the Ink4a/ARF
locus (CDKN2A) was a microdeletion, detectable using PCR ampliﬁca-
tion yet not by FISH (Serakinci et al., 2004) or SKY (Burns et al., 2008),
was conﬁrmed. In addition, aCGH indicated the ~151 kbpmicrodeletion
included an exon ofMTAP in addition to CDKN2a and CDKN2b. Such co-
vert 9p21 deletions were responsible for FISH mis-diagnosis in Ewing
sarcomas (Savola et al., 2007). Down regulation of MTAP expression
concordant with copy number loss has been highlighted in human
tumor samples (Kryukov et al., 2016) and osteosarcomas (Jour et al.,
2016), generating a PRMT5metabolic pathway vulnerability. Higher in-
cidence of p16INK4a deletions in cultured cell lines versus primary gli-
omas, was attributed to a strong cell culture imposed selective
pressure (Hartmann et al., 1999). Indeed, p16INK4a expression has
close association with contact inhibition of growth in human embryo
lung ﬁbroblasts (Wieser et al., 1999) and hBMSC senescence (Shibata
et al., 2007). Nevertheless, beyond the culture environment, p16INK4a
markedly inhibited the proliferation of aged pancreatic islet stem cells
in vivo (Krishnamurthy et al., 2006). The speciﬁc 9p21 CNV loss in
hBMSC-TERT4 was reproduced with a stronger signal in hBMSC-
TERT20 cells, suggesting elaboration of a pre-existing genetic aberra-
tion. This makes it likely that the 9p21 CNV initiated before the
hBMSC-TERT cells were distributed as 1:4 and 1:20 split-ratio-speciﬁc
populations, making this an earlier event than previously described. Of
note, the PCR based method used to detect the 9p21 loss had limited
sensitivity and mosaicism within a heterogeneous population could
allow variant cells to remain undetected (Baker et al., 2016). Translating
a cell speciﬁc growth advantage to a detectable change in growth rate of
the whole population can be delayed in hBMSC cultures (Garcia et al.,
2010) quelling expectation that onemay simply detect genetic instabil-
ity from changes in growth rate kinetics.
Many of the CNV found in all hBMSC-TERT cultures (14/22),
might simply reﬂect a difference pertaining to the comparative ref-
erence control DNA, however bioinformatic STRING based interac-
tions indicated that 10 of these ubiquitous CNV contained genes
interacting with our hBMSC-TERT20 contextual framework for
pathways in cancer. Further interventional experiments beyond
the scope of this manuscript would be needed to verify their
functional contribution. Focusing, rather, on CNV distributed more
heterogeneously among the cell populations, hBMSC-TERT4 cells
had one speciﬁc 21q11.2 CNV loss, whilst non-tumorigenic
hBMSC-TERT20 a 1q44 CNV gain and a 11q13.1 CNV loss that
persisted in all the tumorigenic hBMSC- TERT20 subclones. Such a
cell strain distribution made the latter two events potential pre-
neoplasia biomarkers and notably the 1q44 CNV region harbored
the SMYD3 (Set and MYND domain containing protein 3) oncogene
(Mazur et al., 2014) whilst the 11q13.1 CNV region harbored the
MUS81 (Mus81-Eme1 endonuclease) tumor suppressor gene
(McPherson et al., 2004). Consistent with a role in the replication
stress response (Minocherhomji et al., 2015) and ultrasensitivity
to its expression change (Yu et al., 2008), down-regulation of cross-
over junction endonuclease MUS81 was a prognostic biomarker for
colorectal carcinoma (Wu et al., 2011).
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CNV events don't necessarily change gene expression (Kuijjer et al.,
2012), thus it was reassuring to verify concordant SMYD3 and MUS81
expression changes by gene expression analysis to conﬁrm their poten-
tial signiﬁcance. SMYD3 in particular has been shown to be a transcrip-
tional potentiater of multiple cancer promoting genes in liver and colon
cancer development (Sarris et al., 2016) with potential to promote the
cell cycle (Tsai et al., 2016). Outcomes of increased SMYD3 expression
in cultured cells include reduced contact inhibition and accelerated
growth (Luo et al., 2009) (Ren et al., 2011). KEGG analysis of our contex-
tual framework network indicated components of the PI3K/AKT/mTOR
signaling network and SMYD3 has been shown to be critical for activa-
tion of AKT1 (Yoshioka et al., 2016). Moreover, upregulation of SMYD3
in bladder cancer can promote cancer progression and activate autoph-
agy (Shen et al., 2016), rendering cancer cells resistant to starvation
(Galluzzi et al., 2015), a phenotype highlighted in hBMSC-TERT20
subclones (Burns et al., 2011). Though prevalent in cancers, a role for
SMYD3 in sarcomas has yet to be reported, however p53-mutant mice
only haploinsufﬁcient forMUS81 were already predisposed to develop
sarcomas (Pamidi et al., 2007).
The 11p15.5 CNV gain, closely correlated with hBMSC-TERT strain tu-
morigenicity, contributed the largest number of potential interactors in
our context-deﬁned cancer pathways network. Curiously, despite more
extensive full chromosome 11 imbalance, hBMSC-TERT20-CE8 tumors
arose latently compared to those for the other clones (Burns et al.,
Fig. 6. CNV target gene predicted interactions in contextual frameworks using STRING bioinformatics. A, Graph of interactions within a network derived from prior experimental data for
cancer pathways in hBMSC-TERT cells. Highlighted name nodes correspond to proteins and genes characterized by prior experimental data. B, Graph of interactions within a contextual
framework derived from CNV 1q44 target SMYD3 predicted interacting proteins (blue nodes). C, Graph of interactions within a contextual framework of epigenetic regulator SIRT1
predicted network interacting proteins (green nodes). Highlighted halo nodes correspond to STRING identiﬁed genes within CNV representing a gain (dark node) or loss (pale node)
at the colour-coded locus. Interconnecting edges correspond to STRING predicted protein interactions.
Fig. 5. CNV interacting with hBMSC-TERT20 contextual framework STRING networks. A, Array CGH proﬁle for 1q21.1 and chromosome 1 ideogram, red bar highlights the ~1000 kbp CNV
spanning chr1:147,000,000–148,000,000. B, Array CGH proﬁle for 2q11.2 and chromosome 2 ideogram, red bar highlights the ~100 kbp CNV spanning chr1:99,900,000–100,000,000. C
Array CGH proﬁle for 2q21.1 and chromosome 2 ideogram, red bar highlights the ~225 kbp CNV spanning chr2:130,375,000–130,600,000. D, Array CGH proﬁle for 11q13.1 CNV
speciﬁc to –BD6 cells and chromosome 11 ideogram, red bar highlights the ~65 kbp CNV spanning chr11:65,555,000–65,620,000. E, Array CGH proﬁle for 17q23.2 and chromosome 17
ideogram, red bar highlights the ~50 kbp CNV spanning chr17: 56,700,000–56,750,000. F, Array CGH proﬁle for 22q11.23 and chromosome 22 ideogram, red bar highlights the
~30 kbp CNV spanning chr22:22,685,000–22,715,000. Opposing red arrowheads represent the centrosomic region.
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2008). Conspicuous among the many genes affected by the 570 kbp
11p15.5 CNV gain, HRAS (Hras proto-oncogene, GTPase) was activated
in gliomas by copy number gainsmore frequently than by activatingmu-
tations (Jeuken et al., 2007). Ras activity has context-dependent out-
comes, critically dependent on the pre-existing telomerase and CDKN2A
encoded p16INK4a status of the cells. Though HRAS overexpression can
induce premature senescence in primary human cells, in clonogenic
keratinocytes from the stemcell compartment it could evoke tumorigenic
progression (Maurelli et al., 2016). It may seem counterintuitive that
hBMSC-TERT4 cells bearing a KRAS Q61H activation didn't form tumors,
however, the outcome of KRAS oncogene expression is highly dependent
on cellular context (Guerra et al., 2003) and KRASmutations prove selec-
tive only if they occur in cells with an appropriately abrogated defense
mechanism (Lee and Bae, 2016). Moreover, the status of the wild-type
HRAS isoform continues to inﬂuence mutant KRAS driven signaling
(Bentley et al., 2013) and tumorigenic susceptibility may require KRAS
copy number gains in addition to mutation (Kerr et al., 2016). The
hBMSC-TERT4 phenotype was consistent with recent observations that
over-activation of Kras in immature murine osteoprogenitor cells in-
creased the number of descendent osteoblasts (Papaioannou et al., 2016).
How relevant is the hBMSC-TERT model for guiding ATMP safety?
The “extracurricular” additional activities of ectopic hTERT (Cong and
Shay, 2008) may not only prevent aneuploidy but also introduce an
artefactual bias subverting corrective responses. Extrapolating our re-
sults to primary cultures, needs consideration that hBMSC-TERT cells
may have an enhanced innate tumorigenic risk. Wayward primary
hBMSCmay bemore readily be detected through karyotypic abnormal-
ities and show growth arrest, senescence or apoptosis as appropriate
checkpoint responses that limit tumorigenic risk. Moreover, the time
taken for neoplastic evolution in hBMSC-TERT20 cells was well beyond
typically contemplated ATMP culture periods (Lechanteur et al., 2016).
The hBMSC-TERT20 neoplastic model nonetheless proved that discrete-
ly accrued genetic change in cultured cells could not only accelerate
growth rate, but also drive neoplasia. With authentic tumorigenesis,
the hBMSC- TERT20model has greatest value in revealing relatively co-
vert yet signiﬁcant abnormalities that might ordinarily pass undetected
in short-term cultures. A rare example of spontaneous tumorigenesis
from primary cultured hBMSC veriﬁed by STR proﬁling supports con-
cern for monitoring (Pan et al., 2014), yet even with a “three strikes
you're out”model (Vogelstein and Kinzler, 2015), tumorigenesis need
not be an inevitable outcome. Even with at least three neoplastic con-
tributors, hTERT expression, the 9p21 microdeletion spanning three
checkpoint genes and Kras Q61H activation, subsequently grown
hBMSC-TERT4 cells still formed good quality bone tissue upon experi-
mental implantation. Revisiting our well-characterized neoplastic
modelwith aCGH highlighted extra discriminating events in the tumor-
igenic hBMSC-TERT20 cells, exposed limitations of variously proposed
monitoringmethods and provided further insights into culture-derived
neoplasia. Bioinformatic analysis of CNV locus genes provided strong
supportive evidence that chromosomal changes in the diploid cells con-
tributed to pathways engaging co-existent genetic aberrations to estab-
lish tumorigenic progression. The model provides a richly annotated
experimental framework for future interventional studies verifying
the critical pathways driving neoplasia arisen in stem cells.
The hBMSC-TERT model can guide rational design for improved
predictive genomics (Wang et al., 2015) by introducing novel bio-
markers of neoplastic risk for tailored cost-effective arrays with en-
hanced probe coverage dedicated to safe stem cell expansion (Pan
et al., 2014) and complementary platforms for epigenetic monitor-
ing (Wagner et al., 2016). Our direct experimental evidence that mu-
tation of stem cells with convergence of extrinsic factors can
together create conditions to drive tumorigenesis agrees with what
has been learned from mapping cancer risk in vivo (Zhu et al.,
2016; Shefﬁeld et al., 2017).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2017.09.006.
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